Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year GlaxoSmithKline PLC grew net income 205.59% from 2.76bn to 8.42bn primarily through revenue growth (23.01bn to 23.92bn). For while the costs associated with cost of goods, selling, general and administrative and debt all increased as a percentage of sales, the 3.99% growth in revenues contributed enough to still see net income improve.
Gross margin66.65%
Net profit margin0.31%
Operating margin5.33%
Return on assets0.14%
Return on equity0.84%
Return on investment0.22%
More ▼

Cash flow in GBPView more

In 2015, GlaxoSmithKline PLC increased its cash reserves by 36.20%, or 1.46bn. Cash Flow from Investing totalled 6.04bn, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company generated 2.57bn in cash from operations while cash used for financing totalled 7.10bn.
Cash flow per share0.3755
Price/Cash flow per share44.35
Book value per share0.1178
Tangible book value per share-4.82
More ▼

Balance sheet in GBPView more

GlaxoSmithKline PLC has a Debt to Total Capital ratio of 82.25%, a lower figure than the previous year's 215.48%.
Current ratio0.9322
Quick ratio0.6288
Total debt/total equity34.12
Total debt/total capital0.8225
More ▼

Growth rates in GBP

Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items increased 204.15%. Additionally when measured on a five year annualized basis, dividend per share growth is in-line with the industry average relative to its peers, while earnings per share growth is above the industry average.
Div yield(5 year avg)0.05%
Div growth rate (5 year)4.24%
Payout ratio (TTM)15,635.48%
EPS growth(5 years)40.15
EPS (TTM) vs
TTM 1 year ago
-99.74
More ▼
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.